Category: CBDiary

Towards a Protocol for Treating Glioblastoma

A poster at the recent ICRS meeting —Case Report: Clinical Outcome and Image Response of Two Patients After Chemoradiation Treatment in Association With CBD— gave Joe D. Goldstrich, MD, some confirmation for the protocol he has been using for glioblastoma patients. Here is the poster by Paula B. Dall’Stella, Marcos F. L. Docema, Marcos V. C. Maldaun, Olavo Feher and Carmen L. P. Lancellotti. The authors are in the Department of Neuro-Oncology, Sirio Libanes Hospital, São Paulo, SP, Brazil. Gliomas, the most common primary brain tumors, account for more than 40% of all CNS neoplasms and are highly resistant to the...

Read More

CBD promotes cardiovascular health

Saorise O’Sullivan, PhD, summarized the extremely promising results of her research at this year’s meeting of the International Cannabinoid Research Society in Montreal. O’Sullivan is Associate Proferssor on the Faculty of Medicine and Health Sciences at the University of Nottingham.  Her talk on “Cardiovascular Effects of Cannabinoids” won the ICRS’s Young Investigator Award. Here’s the abstract: Cannabidiol (CBD) is a non-psychoactive phytocannabinoid already on the market as part of a licensed treatment in multiple sclerosis (Sativex® GW Pharmaceuticals, Cambridge, UK). CBD alone (Epidiolex®, GW Pharmaceuticals, Cambridge, UK) is also in clinical trials in children with intractable epilepsies and has...

Read More

$407 for lab testing an LB?

California’s Medical Cannabis Regulation and Safety Act has been passed by the legislature, signed by the governor, and the Administrative State needs until January 1, 2018 to implement it. Dale Gieringer of California NORML reports: “Regulatory costs due to MCRSA are estimated to run between $225 and $873 per pound, according to an economic analysis by the University of California Agricultural Issues Center.  “Over half of the costs are accounted for by testing requirements. This analysis doesn’t include taxes.  The Prop 64 cultivation tax comes to $148/pound —less than the estimated cost of testing.  The analysis also estimates that adult-use production will be...

Read More

‘Treatment’ Providers Ponder MJ Legalization

Kevin Hill’s paper in JAMA March 14, “Cannabis Use and Risk for Substance Use Disorders and Mood or Anxiety Disorders,” caught the attention of Diane Dickinson, MD. Hill is an addiction specialist at McLean Hospital, an affiliate of Harvard Medical School. He begins with an expression of concern:  “Health care professionals often are concerned about whether cannabis use will lead to psychiatric illnesses such as substance use disorders, anxiety disorders, or mood disorders among their patients. Many stakeholders are concerned that an association between cannabis use and psychiatric illnesses will lead to a steady increase in these illnesses as more states...

Read More

Dr. Scott Gottleib to head FDA

GW Pharmaceuticals, Insys, and other companies seeking FDA approval for cannabinoid drugs must have breathed a sigh of relief when Trump chose Scott Gottleib, MD, to head the agency, instead of Jim O’Neill, a libertarian who was in the running. O’Neill may have ditched the agency’s proof-of-efficacy requirement. (It has only been since 1962, BTW,  that the FDA has required drug companies to submit data proving the effectiveness of a new drug. Till then approval was based on evidence of safety.) O’Neill reportedly praised the idea of “letting the market decide” whether new drugs actually work. About Scott Gottleib, Wikipedia tells us: Prior to attending medical...

Read More